Open Access Review Article

The Relation between AEDs and Liver Disease

Ghaydaa Ahmed Shehata*

Professor of Neurology, Assuit University, Egypt

Corresponding Author

Received Date: December 20,2019;  Published Date: January 14, 2020


Abstract

Nowadays, the relationship between epilepsy and liver disease has risen. The prevalence ranged from 5.5 -6.69\1000 in wide epidemiological studies in Egypt (El-Tallawy et al., 2016, El-Tallawy et al., 2013, Farghaly et al., 2013). Antiepileptic drugs (AEDs) are no longer restricted to the treatment of epilepsy. These are widely used in a broad spectrum of psychiatric and neurological disorders. Various liver diseases affect the response to different antiepileptic drugs (AEDs) characteristics to different degrees (Vidaurre et al., 2017) [1]. The liver plays a major role in the metabolism of many of these drugs. Hepatotoxicity is rare, but a real concern when initiating therapy. Likewise, liver disease can adversely affect the biotransformation of some of these drugs. As the disease progresses, the proportion of disrupted liver functions may change, so that acute liver disease may affect AEDs differently than chronic liver failure (Boggs, 2011) [2]. Symptomatic seizures or epilepsy may complicate the course of the hepatic disease to different degrees. Initiating the treatment of antiepileptic therapy in this setting represents a difficult challenge because most AEDs are metabolized by the liver (Vidaurre et al., 2017) [1]. Severe liver disease also affects the binding capacity of (AEDs) to serum proteins, increasing the risk of toxicity. Cirrhosis diminishes total hepatic blood flow but does not impact hepatocyte function until it is severe. Hepatitis may increase hepatic blood flow but diminishes hepatocyte function (Boggs, 2011) [2].

Citation
Signup for Newsletter
Scroll to Top